|
|
Article: Tapentadol hydrochloride treats moderate to severe pain.(PHARMACY CORNER)(Brief article)
- Article from:
- Oncology Nursing Forum
- Article date:
- March 1, 2009
- Author:
CopyrightCOPYRIGHT 2009 Oncology Nursing Society. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Tapentadol hydrochloride (Johnson & Johnson Pharmaceutical), an immediate release analgesic with mu-opioid agonist and norepinephrine reuptake inhibitor properties, has received FDA approval for the treatment of moderate-to-severe acute pain in adults. The drug comes in 50, 75, and 100 mg tablets.
The most common adverse reactions included nausea, dizziness, vomiting, somnolence, and headache. Tapentadol hydrochloride is contraindicated in many patients where mu-opioids are contraindicated and in patients who are taking or have received monoamine oxidase inhibitors within the prior 14 days. In the presence of impaired renal ...